We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Blood-Brain Barrier Opening Device Enables Liquid Biopsy Tests in Brain Tumor Patients

By HospiMedica International staff writers
Posted on 27 Oct 2023

The blood-brain barrier (BBB) serves as a protective shield for the brain, strictly controlling the substances that can move from the bloodstream into the brain. More...

This barrier not only keeps harmful molecules at bay but also limits the reach of potentially beneficial drugs and diagnostic markers, thus preventing measurement using a blood test. Now, a non-invasive medical device that reversibly opens the BBB exactly where it is needed can pave the way for precision medicine, delivering drugs, and measuring circulating biomarkers via a blood test to diagnose and track brain diseases.

Cordance Medical (Mountain View, CA, USA) has developed the NeuroAccess device aimed at adults aged 22 and older who have known or suspected brain tumors. The device allows healthcare experts to non-invasively raise the levels of cell-free DNA (cfDNA) in the bloodstream, enhancing the performance of liquid biopsies for oncology. The device employs focused ultrasound coupled with microbubbles to safely and temporarily open the BBB. With its portable design, the goal is for the NeuroAccess device to be used for SonoBiopsy procedures in various healthcare settings, from community clinics to hospitals.

Earlier in the year, initial studies confirmed the safety and feasibility of using the SonoBiopsy technique in patients with brain tumors. Previous research using focused ultrasound and microbubbles to open the BBB has shown promise for treating various neurological conditions, such as glioblastoma, brain metastasis, Alzheimer's, and Parkinson's. Now, the U.S. Food and Drug Administration has given the NeuroAccess device a Breakthrough Device Designation, indicating its transformative potential for meeting the medical needs of brain tumor patients by offering a safer way to obtain molecular characterization of their tumors.

"This Breakthrough Device Designation from the FDA is a pivotal milestone for Cordance Medical and for patients requiring more efficacious diagnostic solutions," said Ryan Dittamore, CEO of Cordance Medical. "We are keen to continue our clinical trials and to collaborate closely with the FDA to bring this groundbreaking technology to market."

Related Links:
Cordance Medical 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.